Spravato was first approved for use in 2019 to treat people with major depressive disorder who did not respond to at least ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

The large number of people with TRD has driven very high sales expectations for Spravato, with some analysts suggesting sales could reach around $2.3 billion within five years of launch.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Spravato had been cleared in the United States in 2019 to be used together with an oral antidepressant for both treatment-resistant depression and for people with MDD. Related Trump announces $500 ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Depression is serious, and can even be life-threatening. While Spravato isn’t perfect and does have risks, it offers new hope for people who haven’t found relief with other treatments.

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

Previously, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing ...